Urogen Pharma (NASDAQ:URGN) Stock Keeps “Buy” Rating at HC Wainwright

Urogen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report issued on Monday, Benzinga reports. They currently have a $75.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 119.62% from the company’s previous close.

A number of other research analysts also recently issued reports on the stock. Oppenheimer boosted their target price on shares of Urogen Pharma from $40.00 to $50.00 and gave the company an “outperform” rating in a research report on Thursday, July 16th. Guggenheim boosted their target price on shares of Urogen Pharma from $42.00 to $58.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Thursday. UBS Group reiterated a “buy” rating on shares of Urogen Pharma in a research report on Thursday, July 9th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $56.00 target price on shares of Urogen Pharma in a report on Thursday, September 10th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Urogen Pharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $52.38.

Urogen Pharma Trading Down 1.2%

URGN stock traded down $0.41 during trading on Monday, hitting $34.15. The company had a trading volume of 1,257,326 shares, compared to its average volume of 827,069. The business has a 50-day moving average of $43.16 and a 200-day moving average of $35.39. Urogen Pharma has a one year low of $16.36 and a one year high of $50.81. The stock has a market cap of $1.67 billion, a PE ratio of -17.25 and a beta of 1.57.

Urogen Pharma (NASDAQ:URGN) last announced its earnings results on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The company had revenue of $72.46 million during the quarter, compared to analyst estimates of $63.55 million. Research analysts forecast that Urogen Pharma will post -0.20 EPS for the current year.

Insider Buying and Selling

In related news, insider Mark Schoenberg sold 60,677 shares of the stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $47.05, for a total value of $2,854,852.85. Following the transaction, the insider directly owned 59,086 shares in the company, valued at $2,779,996.30. This trade represents a 50.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Jason Smith sold 1,519 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $42.54, for a total value of $64,618.26. Following the completion of the transaction, the general counsel owned 53,141 shares in the company, valued at approximately $2,260,618.14. This represents a 2.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 65,269 shares of company stock worth $3,037,646 in the last ninety days. Corporate insiders own 4.80% of the company’s stock.

Institutional Trading of Urogen Pharma

Institutional investors have recently made changes to their positions in the company. Persistent Asset Partners Ltd bought a new stake in shares of Urogen Pharma in the 2nd quarter worth $66,000. Quantbot Technologies LP bought a new stake in shares of Urogen Pharma in the 2nd quarter worth $78,000. Glenmede Trust Co. NA bought a new stake in shares of Urogen Pharma in the 1st quarter worth $189,000. The Manufacturers Life Insurance Company bought a new stake in shares of Urogen Pharma in the 2nd quarter worth $412,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Urogen Pharma in the 2nd quarter worth $431,000. Institutional investors own 91.29% of the company’s stock.

About Urogen Pharma

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for cancers of the urinary tract. The company’s platform is based on RTGel, a proprietary reverse-thermal hydrogel designed to retain medicines in the urinary tract and provide localized treatment while limiting systemic exposure.

UroGen’s lead commercial product is JELMYTO (mitomycin), a gel-based therapy approved by the U.S. Food and Drug Administration for the primary chemoablation of low-grade upper tract urothelial cancer in adults.